Company
Seagen
Seagen has 17 drugs tracked on RxWires: 4 in Phase 3, 6 in Phase 2, 1 in Phase 1/2, 6 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Trastuzumab Emtansine | Phase 3 | Anatomic Stage II Breast Cancer AJCC v8 |
| Brentuximab vedotin | Phase 3 | Diffuse Large B-cell Lymphoma |
| Tucatinib | Phase 3 | HER2 Positive Breast Cancer |
| sigvotatug vedotin | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Biospecimen Collection | Phase 2 | Bladder Squamous Cell Carcinoma |
| SGN-15 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
| 5-Fluorouracil continuous infusion FOLFOXIRI schedule | Phase 2 | Stage II Colon Cancer |
| tisotumab vedotin | Phase 2 | Ovarian Cancer |
| SGN-40 | Phase 2 | Lymphoma, Large B-Cell, Diffuse |
| Enfortumab vedotin | Phase 2 | Muscle Invasive Bladder Urothelial Carcinoma |
| ladiratuzumab vedotin | Phase 1/2 | Triple Negative Breast Neoplasms |
| SEA-BCMA | Phase 1 | Multiple Myeloma |
| Mogamulizumab | Phase 1 | Cutaneous T Cell Lymphoma |
| lintuzumab | Phase 1 | Myelodysplastic Syndrome (MDS) |
| ACTR087 | Phase 1 | Multiple Myeloma |
| SGN-CD228A | Phase 1 | Cutaneous Melanoma |
| SEA-CD70 | Phase 1 | Myelodysplastic Syndrome |
Latest
Follow Seagen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.